Asahi Kasei Pharma’s licensing partner, Dong-A ST Co., Ltd. (Dong-A ST), obtained approval on November 13, 2015, from Korea’s Ministry of Food and Drug Safety (MFDS) for the sale of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: Teribone™ 56.5 µg subcutaneous injection) for the treatment of osteoporosis in postmenopausal women at high risk of bone fracture.

Asahi Kasei Pharma and Dong-A ST concluded a license agreement in October 2014 granting Dong-A ST exclusive rights for the development and sale of Teribone™ in Korea, and Dong-A ST filed an application for approval in December 2014. Dong-A ST will begin the sale of Teribone™ in Korea in the spring of 2016.

Asahi Kasei Pharma believes that through Dong-A ST’s effort to quickly facilitate its widespread use, Teribone™ will make a significant contribution to the treatment of osteoporosis in Korea.

Corporate profile of Dong-A ST Co., Ltd.

1. President

   Kang Soo-Hyoung

2. Head office

   Seoul, Korea

3. Paid-in capital

   38.5 billion won

4. Business line

   Manufacture and sale of pharmaceuticals

5. Net sales

   568.1 billion won (January–December 2014)

6. Employees

   1,582 (as of December 31, 2014)